References
- Beksac K, Orgul G, Can GS, Oktem A, Kav T, Beksac MS. Management of inflammatory bowel disease and pregnancy using prophylactic low dose low molecular weight heparin and corticosteroids. J Clin Diagn Res. 2017;11(11). QR01–QR03.
- Beksac K, Aktoz F, Orgul G, Celik HT, Ozgu-Erdinc AS, Beksac MS. Pregnancy in papillary thyroid cancer survivors. J Turkish German Gynecol Assoc. 2018;19(2):94–97. doi:https://doi.org/10.4274/jtgga.2017.0057.
- Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117(3):632–639. doi:https://doi.org/10.1016/S0016-5085(99)70456-7.
- Shaffer EA. Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20(6):981–996. doi:https://doi.org/10.1016/j.bpg.2006.05.004.
- Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–187. doi:https://doi.org/10.5009/gnl.2012.6.2.172.
- Sakuta H, Suzuki T. Plasma total homocysteine and gallstone in middle-aged Japanese men. J Gastroenterol. 2005;40(11):1061–1064. doi:https://doi.org/10.1007/s00535-005-1691-z.
- Afghani R, Aminian A, Mirsharifi SR, et al. Serum homocysteine level and gall stone disease: a case control study. Tehran Univ Med J TUMS Publ. 2010;68(8):481–486.
- Lieske JC, De La Vega LP, Slezak J, et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760–764. doi:https://doi.org/10.1038/sj.ki.5000150.
- Demir E, Izol V, Aridogan IA, Paydas S, Tansug Z, Erken U. Immediate and long-term high levels of plasma homocysteine after extracorporeal shock wave lithotripsy in patients with renal stone disease. Clin Exp Nephrol. 2014;18(4):623–625. doi:https://doi.org/10.1007/s10157-013-0884-7.
- Eskes TK. Clotting disorders and placental abruption: homocysteine—a new risk factor. Eur J Obstet Gynecol Reprod Biol. 2001;95(2):206–212. doi:https://doi.org/10.1016/S0301-2115(00)00492-9.
- Bhargava S, Tyagi SC. Nutriepigenetic regulation by folate-homocysteine-methionine axis: a review. Mol Cell Biochem. 2014;387(1-2):55–61. doi:https://doi.org/10.1007/s11010-013-1869-2.
- Ozek MA, Karaagaoglu E, Orgul G, Gumruk F, Yurdakök M, Beksac MS. Comparison of different types of twin pregnancies in terms of obstetric and perinatal outcomes: association of vanished twins with methylenetetrahydrofolate reductase (MTHFR) polymorphism(s). J Assist Reprod Genet. 2018;35(12):2149–2154. doi:https://doi.org/10.1007/s10815-018-1346-7.
- Graham IM, Daly LE, Refsum HM. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA. 1997;277(22):1775–1781. doi:https://doi.org/10.1001/jama.1997.03540460039030.
- Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003;17(3):459–469. doi:https://doi.org/10.1016/S1521-6934(03)00009-9.
- Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrafolatereductase. Nat Genet. 1995;10(1):111–113. doi:https://doi.org/10.1038/ng0595-111.
- Beksaç MS, Aydın E, Tuğral M, Karaağaoğlu E. An obstetrics index for the assessment of risk levels of “high risk pregnancy” groups. Gynecol Obstet Reprod Med. 2016;21(1):10–13.
- Fadiloglu E, Unal C, Beksac MS. Management and the pregnancy outcomes of patients positive for anti-parietal cell antibody. Hum Antibodies. 2019;27(2):111–116. doi:https://doi.org/10.3233/HAB-180355.
- Baggott JE, Tamura T. Homocysteine, iron and cardiovascular disease: a hypothesis. Nutrients. 2015;7(2):1108–1118. doi:https://doi.org/10.3390/nu7021108.
- Quinlivan EP, McPartlin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet (London, England). 2002;359(9302):227–228. doi:https://doi.org/10.1016/S0140-6736(02)07439-1.
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338(15):1042–1050. doi:https://doi.org/10.1056/NEJM199804093381507.
- Karlidag I, Abat D, Altunkol A, Izol V, Demir E, Aridogan IA. Is the homocysteine level a good predictive marker for evaluating kidney function in patients after percutaneous nephrolithotomy. Urol J. 2018;15(4):153–157. doi:https://doi.org/10.22037/uj.v0i0.3917.
- Van der Molen E, Verbruggen B, Novakova I, Eskes T, Monnens L, Blom H. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG Int J Obstet Gynaecol. 2000;107(6):785–791. doi:https://doi.org/10.1111/j.1471-0528.2000.tb13341.x.